Frederic Lehmann

As the former Head of Clinical Development and Medical Affairs and Vice President of Celyad Oncology, Dr. Frederic Lehmann defined the strategic vision and contributed to securing a number of autologous and allogeneic engineered T-cell therapy IND candidates. He also spent 12 years at GSK in several roles including Head of the Early Clinical Development Business Unit for Cancer Immunotherapeutics in the company's Vaccine Division.